This clinical study is evaluating a new treatment for PKD1 mutation-associated autosomal dominant polycystic kidney disease (ADPKD), a condition that results in kidney failure. The primary goal is to assess the safety and tolerability of the treatment in adults with confirmed PKD1 mutation-associated ADPKD.
Be 18 to 60 years old
Male or female
